AEGEA Medical Inc. announced that it has received $40 million in funding from Perceptive Advisors LLC, Alloy Ventures, Inc., Delphi Ventures, BioMed Ventures LP, Solas Bioventures, Medtronic plc
January 01, 2018
Share
AEGEA Medical Inc. announced that it has received $40 million in a round of funding on January 2, 2017. The transaction involved participation from new investor Perceptive Advisors LLC for $30 million, existing investors Medtronic plc (NYSE:MDT), Alloy Ventures, Inc., Delphi Ventures, BioMed Ventures LP, and Solas Bioventures.
Medtronic plc is one of the world leaders in designing, manufacturing and marketing of medical equipment. Net sales break down by sector of activity as follows:
- general and minimally invasive surgery (28.8%): surgical equipment, intra-operative monitoring systems, ventilation systems, etc.;
- cardiac rhythm management (18.6%): implantable cardiac pacemakers, implantable defibrillators and automatic external defibrillators, cardiac ablation probes, etc.;
- vascular diseases and cardiac surgery (17.4%): coronary stents, endoprostheses for aortal pathologies, distal protection systems, catheters, heart valve prostheses, auto-transfusion equipment, cardiac ablation devices, etc.;
- spinal disorders (14.1%): spinal prostheses, disc prostheses, cerebral stimulation systems, bone graft technologies and mini-invasive spinal surgery, etc. The group also develops medical imagery-guided surgical navigation systems activity;
- neurovascular, ear, nose and throat (ENT) and pelvic diseases (8.2%);
- diabetes management (7.4%): internal and external glycemia monitoring systems and insulin pumps;
- neurological disorders (5.5%): neurostimulation and pumped medication administration products, diagnostic tools, etc.
Net sales are distributed geographically as follows: Ireland (0.3%), the United States (50.9%) and other (48.8%).
AEGEA Medical Inc. announced that it has received $40 million in funding from Perceptive Advisors LLC, Alloy Ventures, Inc., Delphi Ventures, BioMed Ventures LP, Solas Bioventures, Medtronic plc